Wednesday, April 13, 2016

Peptides for CNS and Alzheimer's Disease Therapy

Exclusive TIDES 2016 interview with Dieter Willbold, Ph.D., Director, ICS-6 Structural Biochemistry, Forschungszentrum J├╝lich, Germany. Dr. Willbold gives us some exclusive insights into the topics he will be addressing onstage at the 18th annual TIDES in just 4 weeks time. Don't miss out on this record setting meeting; join over 800 global attendees over 4 days full of insights and learnings. Register for TIDES by Friday, 4/15 and save $300 - Use the code B16180BLOG.


Dr. Willbold Interview: 

What current challenges are you facing for advancing your promising peptide for Alzheimer's disease through clinical trials?

Our main focus at the moment is to finish all the necessary preclinical tox and safety tests in order to soon get permission for a clinical phase I study with our drug candidate.

One challenge for developing therapeutics like ours that target specific aggregate species, lies in the lack of suitable analytics to measure target engagement, because most methods don't differentiate between different aggregate sizes. In addition to cognitive behavioral tests, we ourselves have therefore developed novel methods to measure efficacy and target engagement .e.g. QIAD (short for quantitative determination of interference with aggregate size distribution; Brener et al., Scientific Reports 2015), which measures Abeta oligomer elimination efficiency.


What are the advantages of peptide therapeutics over small molecules, antibodies and other protein therapeutics?

Small molecules often lack specificity, and this can lead to serious side effects and autoimmune responses. On the other hand protein-based therapeutics like antibodies possess high target selectivity and are made of natural components, but they are very big and expensive molecules. They often suffer from low oral bioavailability.

Small peptides can offer the best of both worlds in some respects: They are more target specific than small molecules but easier to produce than protein based drugs. Our drug candidate is made solely from D-enantiomeric amino acid residues and has surprisingly good oral bioavailability.


Where do you see innovation happening in the peptide field over the next 5 years?

Innovation will certainly happen in the production of peptides (cost reduction) and in the formulation of peptides (increase oral bioavailability).


______________________________________________________



Reserve your seat today to attend TIDES 2016 in Long Beach, CA and hear Dr. Willbold deliver a live presentation "Efficiency and Oral Bioavailability of Abeta Oligomer Directed D-Enantiomeric Peptides Developed for Therapy of Alzheimer's Disease", where he will delve into small soluble Abeta oligomers are suspected to be the major toxic species responsible for development and progression of Alzheimer's disease (AD). We developed highly potent D-enantiomeric peptide compounds that specifically eliminate Abeta oligomers and improve cognitive performance and stop or slow down neurodegeneration of AD transgenic mice. Data on stability and oral bioavailability clearly support the superiority of D-peptides over L-peptides.





Share this article with your social network, just click below to share now!


No comments :

Post a Comment